Related Content
- Pfizer forms licensing agreement with Seattle Genetics
- Adherence among chronic disease patients can lead to big savings
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
- Moving PSE to Rx-only in Mo. lacks fiscal sense
MORRISTOWN, N.J. — Watson Labs has begun shipping a drug designed to treat partial onset seizures in patients with epilepsy.
The drug maker said it launched levetiracetam extended-release tablets in the 500-mg and 750-mg strengths. The drug is a generic version of UCB's Keppra XR. The drug is indicated to treat patients ages 16 years and older.
Watson said it began shipping the drug on Tuesday following approval of its abbreviated new drug application from the Food and Drug Administration.
